TY - JOUR
T1 - Resolution of tissue signatures of therapy response in patients with recurrent GBM treated with neoadjuvant anti-PD1
AU - Lu, Yue
AU - Ng, Alphonsus H.C.
AU - Chow, Frances E.
AU - Everson, Richard G.
AU - Helmink, Beth A.
AU - Tetzlaff, Michael T.
AU - Thakur, Rohit
AU - Wargo, Jennifer A.
AU - Cloughesy, Timothy F.
AU - Prins, Robert M.
AU - Heath, James R.
N1 - Funding Information:
This study was funded by Ben and Catherine Ivy Foundation, the Parker Institute for Cancer Immunotherapy (PICI), the Andy Hill Cancer Research Endowment (CARE), the National Institutes of Health SPORE in Brain Cancer (P50CA211015), NIH/NCI grant (U01 CA217655 (J.R.H.) and 1R01CA222695-01), the Brain Tumor Funder’s Collaborative, and the Cancer Research Institute. We gratefully acknowledge the technical assistance of Liuliu Pan, Joey R. Orpilla, and Arya Bahrami.
Publisher Copyright:
© 2021, The Author(s).
PY - 2021/12/1
Y1 - 2021/12/1
N2 - The response of patients with recurrent glioblastoma multiforme to neoadjuvant immune checkpoint blockade has been challenging to interpret due to the inter-patient and intra-tumor heterogeneity. We report on a comparative analysis of tumor tissues collected from patients with recurrent glioblastoma and high-risk melanoma, both treated with neoadjuvant checkpoint blockade. We develop a framework that uses multiplex spatial protein profiling, machine learning-based image analysis, and data-driven computational models to investigate the pathophysiological and molecular factors within the tumor microenvironment that influence treatment response. Using melanoma to guide the interpretation of glioblastoma analyses, we interrogate the protein expression in microscopic compartments of tumors, and determine the correlates of cytotoxic CD8+ T cells, tumor growth, treatment response, and immune cell-cell interaction. This work reveals similarities shared between glioblastoma and melanoma, immunosuppressive factors that are unique to the glioblastoma microenvironment, and potential co-targets for enhancing the efficacy of neoadjuvant immune checkpoint blockade.
AB - The response of patients with recurrent glioblastoma multiforme to neoadjuvant immune checkpoint blockade has been challenging to interpret due to the inter-patient and intra-tumor heterogeneity. We report on a comparative analysis of tumor tissues collected from patients with recurrent glioblastoma and high-risk melanoma, both treated with neoadjuvant checkpoint blockade. We develop a framework that uses multiplex spatial protein profiling, machine learning-based image analysis, and data-driven computational models to investigate the pathophysiological and molecular factors within the tumor microenvironment that influence treatment response. Using melanoma to guide the interpretation of glioblastoma analyses, we interrogate the protein expression in microscopic compartments of tumors, and determine the correlates of cytotoxic CD8+ T cells, tumor growth, treatment response, and immune cell-cell interaction. This work reveals similarities shared between glioblastoma and melanoma, immunosuppressive factors that are unique to the glioblastoma microenvironment, and potential co-targets for enhancing the efficacy of neoadjuvant immune checkpoint blockade.
UR - http://www.scopus.com/inward/record.url?scp=85108953275&partnerID=8YFLogxK
U2 - 10.1038/s41467-021-24293-4
DO - 10.1038/s41467-021-24293-4
M3 - Article
C2 - 34188042
AN - SCOPUS:85108953275
SN - 2041-1723
VL - 12
JO - Nature communications
JF - Nature communications
IS - 1
M1 - 4031
ER -